Application Detail

Description of Medical Service

Axicabtagene ciloleucel is a CAR T-cell therapy that is produced using a patient’s own T-cells. A patient’s T-cells are collected and genetically modified in a lab to express an anti-CD19 chimeric antigen receptor that targets the lymphoma B-cells. The modified T-cells are multiplied and then infused back into the patient where they target and kill the cancerous lymphoma B-cells. Axicabtagene ciloleucel is used when patients with follicular lymphoma do not respond to (refractory), or relapse (come back) after, other types of treatment, such as chemotherapy.

Description of Medical Condition

Follicular Lymphoma (FL) is a type of blood cancer that changes certain blood cells in your body called B-cell lymphocytes. It can affect lymph nodes and the lymphatic system. Follicular lymphoma is considered an indolent lymphoma, which means it is usually slow growing.

Reason for Application

Highly Specialised Therapy – National Health Reform Agreement

Medical Service Type

Investigative technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Summary and PICO Set

Application Summary (PDF 381 KB)
Application Summary (Word 23 KB)

PICO Set Document (PDF 1063 KB)
PICO Set Document (Word 405 KB)

Consultation Survey

Consultation Survey (PDF 653 KB)
Consultation Survey (Word 32 KB)

PASC Consultation
Expedited - Bypassing PASC

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 14 June 2024 for it to be considered by MSAC at its August 2024 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

Bypassing PASC

ESC

13-14 June 2024

MSAC

1-2 August 2024